Eric Bruening
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$7.1MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $7.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 11, 2019 | NIH | SBIR Phase II A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B | $1.0M | TOMEGAVAX, INC. |
| Aug 20, 2018 | NIH | SBIR Phase II A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B | $1.7M | TOMEGAVAX, INC. |
| Aug 21, 2017 | NIH | SBIR Phase II A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses | $928K | TOMEGAVAX, INC. |
| May 16, 2017 | NIH | SBIR Phase II A human cytomegalovirus-based immunotherapy for HIV-1 | $986K | TOMEGAVAX, INC. |
| Mar 3, 2017 | NIH | SBIR Phase II A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B | $297K | TOMEGAVAX, INC. |
| Sep 19, 2016 | NIH | SBIR Phase II A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses | $948K | TOMEGAVAX, INC. |
| Jul 8, 2016 | NIH | SBIR Phase I A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine | $225K | TOMEGAVAX, INC. |
| May 8, 2015 | NIH | SBIR Phase II A human cytomegalovirus-based immunotherapy for HIV-1 | $987K | TOMEGAVAX, INC. |
Peer ranks
Federal funding#139
Awards as PI#190
Patents#273
Companies
- TOMEGAVAX, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.